

PFIZER INC
Form 8-K
January 23, 2008
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **January 23, 2008**

PFIZER INC.
(Exact name of registrant as specified in its charter)

Delaware 1-3619 13-5315170
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
235 East 42nd Street

New York, New York 10017
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code:
(212) 573-2323

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On January 23, 2008, Pfizer Inc. ("Pfizer") issued a press release announcing its financial results for the fourth quarter of 2007. The information contained in the press release is deemed to be "filed" under the Securities Exchange Act of 1934 as Exhibit 99 to this report, and such press release is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99 - Press Release of Pfizer Inc. dated January 23, 2008, reporting Pfizer's financial results for the fourth quarter of 2007. Exhibit 99 is deemed to be "filed" under the Securities Exchange Act of 1934 in this Current Report on Form 8-K.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PFIZER INC.

By: /s/ Margaret M. Foran

Margaret M. Foran

Title: Senior Vice President-Corporate Governance,
Associate General Counsel and Corporate Secretary

Dated: January 23, 2008

EXHIBIT INDEX

Exhibit No. Description

99 Press Release of Pfizer Inc. dated January 23, 2008, reporting Pfizer's financial results for the fourth quarter of 2007.